Biren Amin
Stock Analyst at Piper Sandler
(3.55)
# 900
Out of 5,161 analysts
69
Total ratings
44.26%
Success rate
8.32%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $77.50 | +80.65% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.68 | +316.67% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $5.11 | +213.11% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $4.84 | +44.63% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $24.00 | +100.00% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $17.04 | -6.10% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $67.98 | +44.16% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $11.82 | +466.84% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $8.87 | +249.49% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $57.60 | +64.93% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $6 | $3.51 | +70.94% | 1 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4.5 → $4 | $3.09 | +29.45% | 1 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $7.71 | +120.49% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.47 | +183.40% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $27.25 | +39.48% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.19 | +131.21% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $35.47 | +100.17% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.59 | +264.96% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $20.99 | +0.05% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $114.29 | +0.62% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $18.39 | +74.01% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $2.98 | +0.67% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.75 | +2,445.45% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.17 | +30,203.03% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $4.67 | +413.92% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.61 | +637.53% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.30 | +168,363.61% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.41 | +48.78% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $746.61 | -7.45% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.87 | +105.34% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $63.79 | +58.33% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $127.78 | -46.00% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $478.13 | -67.58% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $7.69 | +1,668.53% | 4 | Mar 6, 2017 |
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $77.50
Upside: +80.65%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.68
Upside: +316.67%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $5.11
Upside: +213.11%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $4.84
Upside: +44.63%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $24.00
Upside: +100.00%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $17.04
Upside: -6.10%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $67.98
Upside: +44.16%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $11.82
Upside: +466.84%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $8.87
Upside: +249.49%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $57.60
Upside: +64.93%
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.51
Upside: +70.94%
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $3.09
Upside: +29.45%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $7.71
Upside: +120.49%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $2.47
Upside: +183.40%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $27.25
Upside: +39.48%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.19
Upside: +131.21%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $35.47
Upside: +100.17%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $9.59
Upside: +264.96%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $20.99
Upside: +0.05%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $114.29
Upside: +0.62%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $18.39
Upside: +74.01%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $2.98
Upside: +0.67%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.75
Upside: +2,445.45%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.17
Upside: +30,203.03%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $4.67
Upside: +413.92%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.61
Upside: +637.53%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.30
Upside: +168,363.61%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.41
Upside: +48.78%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $746.61
Upside: -7.45%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.87
Upside: +105.34%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $63.79
Upside: +58.33%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $127.78
Upside: -46.00%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $478.13
Upside: -67.58%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $7.69
Upside: +1,668.53%